BioNTech
In a watershed moment for the biotechnology sector, BioNTech SE (NASDAQ: BNTX) has reported its full-year 2025 financial results, signaling the definitive end of the COVID-19 vaccine gold rush and the beginning of a high-stakes pivot toward oncology. The German biotech pioneer recorded a net loss of €1.1 billion
Pfizer
NEW YORK — Pfizer Inc. (NYSE: PFE) has announced breakthrough results from its Phase 3 BREAKWATER clinical trial, demonstrating that its BRAFTOVI (encorafenib) regimen significantly improves both progression-free survival (PFS) and overall survival (OS) in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC). The data, bolstered by a fresh topline report
ASCO GU 2026
As the oncology community prepares to descend upon San Francisco for the 2026 ASCO Genitourinary (GU) Cancers Symposium from February 26–28, investors and clinicians alike are bracing for data that could redefine the standard of care in bladder and kidney cancers. With the conference just ten days away, the
Moderna
In a landmark moment for the future of personalized medicine, Moderna, Inc. (NASDAQ: MRNA) and Merck & Co., Inc. (NYSE: MRK) announced groundbreaking five-year follow-up data on January 20, 2026, for their experimental mRNA cancer vaccine. The results, stemming from the Phase 2b KEYNOTE-942 trial, demonstrated that the combination of
Olema Pharmaceuticals
Olema Pharmaceuticals (NASDAQ:OLMA) has become the latest focal point of biotech volatility and executive opportunism. Following a staggering 300% surge in its share price over the past year—fueled by a "rising tide" effect in the breast cancer treatment market—top insiders have begun offloading significant portions
Revolution Medicines
The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood City-based oncology specialist experienced a roller-coaster session following reports that Big Pharma titan AbbVie (NYSE: ABBV) was in advanced discussions
Pfizer
NEW YORK — On December 16, 2025, Pfizer (NYSE:PFE) issued a conservative financial outlook for the 2026 fiscal year, falling short of Wall Street’s expectations and signaling a prolonged period of transition for the pharmaceutical giant. The guidance, which highlights the dual pressures of declining COVID-19 product demand and
CTOR
CRANFORD, NJ — As the 2025 calendar year draws to a close, Citius Oncology, Inc. (Nasdaq: CTOR) has reached a pivotal juncture in its corporate evolution. Following the release of its SEC 10-K filing for the fiscal year ended September 30, 2025, the company has officially shed its "development-stage"
Nuvation Bio
Boston, MA – November 19, 2025 – Nuvation Bio Inc. (NASDAQ: NUVB) has captured the financial spotlight, witnessing a remarkable 47.71% surge in its stock price following a stellar third-quarter 2025 earnings report. The biopharmaceutical company not only significantly surpassed revenue forecasts but also celebrated the highly successful commercial launch of
Nurix Therapeutics
San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the initiation of its pivotal Phase 2 DAYBreak clinical study. This critical advancement focuses on bexobrutideg (NX-5948), an investigational Bruton's tyrosine kinase
Turnstone Biologics
October 17, 2025 – In the volatile world of biotechnology, ambitious price targets often fuel investor speculation and market buzz. However, for Turnstone Biologics Corp. (NASDAQ: TSTN), the notion of its stock reaching a $100 valuation stands in stark contrast to its current precarious financial and operational state. Despite the transformative
Leap Therapeutics
Boston, MA – October 3, 2025 – Leap Therapeutics, Inc. (NASDAQ: LPTX) experienced a sharp downturn in its stock performance today, with shares falling by over 20% in intraday trading. This significant decline marks a notable correction for the biotechnology company, which had seen its stock surge dramatically in the preceding days,